Inflammatory bowel disease

TY - JOUR

T1 - Inflammatory bowel disease

AU - Hansen, Richard

AU - Cameron, Fiona Louise

AU - Hold, Georgina Louise

AU - El-Omar, Emad Munir

AU - Russell, Richard Kay

N1 - Funding Information: The authors wish to acknowledge funding from the Broad Foundation , USA, and the Chief Scientist Office , Scotland. RH is funded by a fellowship from the Chief Scientist Office in Scotland.

PY - 2010/10

Y1 - 2010/10

N2 - Inflammatory bowel disease (IBD) describes a heterogeneous group of chronic inflammatory diseases of the gastrointestinal tract, of which Crohn's disease and ulcerative colitis are the most common diagnoses. About a quarter of IBD presents in childhood, and the phenotype seen involves a wider disease distribution in both Crohn's and ulcerative colitis than seen in adult-onset disease. The incidence of IBD appears to be rising and although we understand more about the genetic, immunological and environmental contributors to aetiology, we do not yet fully understand this rise. In paediatric practice, IBD and in particular Crohn's disease, often results in impaired weight gain, poor linear growth and delayed puberty. Multiple treatment modalities exist for IBD from longstanding treatments such as steroids and immunosuppressants to modern, targeted therapies such as infliximab. This review discusses the current state of the art of clinical practice in relation to paediatric IBD.

AB - Inflammatory bowel disease (IBD) describes a heterogeneous group of chronic inflammatory diseases of the gastrointestinal tract, of which Crohn's disease and ulcerative colitis are the most common diagnoses. About a quarter of IBD presents in childhood, and the phenotype seen involves a wider disease distribution in both Crohn's and ulcerative colitis than seen in adult-onset disease. The incidence of IBD appears to be rising and although we understand more about the genetic, immunological and environmental contributors to aetiology, we do not yet fully understand this rise. In paediatric practice, IBD and in particular Crohn's disease, often results in impaired weight gain, poor linear growth and delayed puberty. Multiple treatment modalities exist for IBD from longstanding treatments such as steroids and immunosuppressants to modern, targeted therapies such as infliximab. This review discusses the current state of the art of clinical practice in relation to paediatric IBD.

KW - Children

KW - Crohn's disease

KW - Inflammatory bowel disease

KW - Treatment

KW - Ulcerative colitis

UR - https://www.scopus.com/pages/publications/77957277541

U2 - 10.1016/j.paed.2010.04.005

DO - 10.1016/j.paed.2010.04.005

M3 - Review article

AN - SCOPUS:77957277541

SN - 1751-7222

VL - 20

SP - 473

EP - 478

JO - Paediatrics and Child Health

JF - Paediatrics and Child Health

IS - 10

ER -